• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

Unlocking Success to Biotech Global Expansion: A Stepwise Game Plan for International Launch

Monday, June 03, 2024
Breakout Session
Emerging Opportunities in Global Markets
26B
In 2022, among drugs launched internationally, markets outside the US accounted for ~35% of total revenues. Between 2010 and 2020, the median global peak revenue of assets launched internationally was $625 million, compared with $152 million for those launched in the US market only. Either as first-time or more seasoned launchers, many biotech companies have gone beyond their home base or are thinking to expand to capture more growth, maximize the impact of their therapies, and help more patients internationally. However, navigating international markets and establishing a strong presence can be a complex endeavor. To unlock success in biotech global expansion, it is critical for companies to select and prioritize countries, design country entry models and strategies, develop launch sequence, and establish cross-functional capabilities. This session will provide a guide on how to approach these critical steps, offering valuable insights on what strategic options are available, what factors to consider, what are some country-specific nuances such as market access and regulatory requirements, what are critical watchout areas, to name a few.
Moderator
Eduardo Schur
US Health Sciences & Wellness Commercial Strategy and R&D Lead
EY (Ernst & Young)
Speakers
Tolga Tanguler
CCO
Alnylam Pharmaceuticals
Russell Cox
President & CEO
Epirium Bio
Robert LaCaze
CEO
Mnemo Therapeutics
Ger Brophy
Chair of the Scientific Advisory Board and retiring EVP Biopharma Production
Avantor
Jérôme Revole
Managing Director Healthcare and Lifesciences
Business France North America
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS